Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Brief Summary: This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma


Options:
A: Arm Label: Phase 2 Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: Cisplatin, Drug: Placebo | Arm Label: Phase 1b; Type: OTHER; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: AMG 102; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2 Arm C
B: Arm Label: Rilotumumab; Type: EXPERIMENTAL; Interventions: Drug: Rilotumumab, Drug: Epirubicin, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Epirubicin, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Rilotumumab; Assigned to Arm(s): Rilotumumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Placebo, Rilotumumab | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Placebo, Rilotumumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Placebo, Rilotumumab
C: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Capecitabine, Drug: Cisplatin, Drug: 5-fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Cisplatin, Drug: Placebo, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Bevacizumab, Placebo
D: Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 3mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 10mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386 placebo, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: AMG 386 placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: AMG 386 10mg/kg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: AMG 386 3mg/kg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): B

Answer: B